Evidence Table B2. CONTINUOUS outcomes for class KERATOLYTIC (TOPICAL).

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target *Within P*	Comparator Data Type: Mean (SD)	Comparator *Within P*	Between P-value
	B.01.01			**Azelaic acid**		**Placebo**		
77 ↑ N=40 Parallel		**Inflammatory change (%)**	Mid (12)	Percent change: -50		Percent change: -10		**0.001**
		Non-inflammatory change (%)	Mid (12)	Percent change: -50		Percent change: -25		**0.027**
	B.01.01			**Azelaic acid**		**Vehicle**		
187 ↑ N=92 Parallel Mod		**Comedones change (%)**	Mid (12)	Percent change: -56		Percent change: 0		**0.05**
		Inflammatory (count/median)	Mid (12)	Measure: 7		Measure: 16		**0.05**
	B.01.02			**Azelaic acid**		**Benzoyl peroxide**		
52 N=309 Parallel Mild		**Inflammatory (count/median)**	Short (4)	Measure: 11	*sig*	Measure: 9	*sig*	
		Overall change/physician (%)	Short (4)	Percent change: 28		Percent change: 32		
		Inflammatory (count) Baseline counts: 19 (Target) / 18		Percent Change*: -63		Percent Change*: -78		
		Overall change/physician (%)		Percent change: 47		Percent change: 50		
		Good/excellent response (%)		Percent change: 70		Percent change: 74		
		Inflammatory (count/median)						
↓ N=30 Parallel Mild/mod		**Acne change (% face)**						
		Face oiliness change (% face)						
		Acne change (% face)						
		Face oiliness change (% face)						
Parallel Mild/mod		**Inflammatory (count)** Baseline counts: 32 (Target) / 32		Percent Change*: -09		Percent Change*: -03		

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target Data Type: Mean (SD)	Target Within P	Comparator Data Type: Mean (SD)	Comparator Within P	Between P-value
95 Parallel Mild/mod		**Non-inflammatory (count)** Baseline counts: 50 (Target) / 50		Percent Change*: -28		Percent Change*: -18		
		Overall change/patient (scale)						
		Total lesions (count) Baseline counts: 83 (Target) / 83		Percent Change*: -18		Percent Change*: -10		
		Inflammatory (count) Baseline counts: 32 (Target) / 32		Percent Change*: -28		Percent Change*: -09		
		Non-inflammatory (count) Baseline counts: 50 (Target) / 50		Percent Change*: -46		Percent Change*: -26		
		Overall change/patient (scale)						
		Total lesions (count) Baseline counts: 83 (Target) / 83		Percent Change*: -40		Percent Change*: -16		
		Count location: Face.						
		Comedones (count) Count location: Face. Baseline counts: 50 (Target) / 50 (Comparator)	Short (4)	Percent Change*: -30	*NS*	Percent Change*: -26	*NS*	
		Erythema Count location: Face.	Short (4)	Measure: 2	*NS*	Measure: 3	*NS*	**NS**
		Papules (count) Count location: Face. Baseline counts: 29 (Target) / 41 (Comparator)	Short (4)	Percent Change*: -31	*.01*	Percent Change*: -38	*.01*	**NS**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Comparison	Continuous Outcome Name (Units) Definition/Comments		Target Data Type: Mean (SD)	Target Within P	Data Type: Mean (SD)	Within P	Between P-value
101 N=59 Parallel Mod		**Peeling** Count location: Face.	Short (4)	Measure: 1	*NS*	Measure: 1	*NS*	**NS**
		Pustules (count) Count location: Face. Baseline counts: 13 (Target) / 13 (Comparator)	Short (4)	Percent Change*: -62	*.03*	Percent Change*: -40	*.03*	**NS**
		Comedones (count) Count location: Face. Baseline counts: 50 (Target) / 50 (Comparator)	Mid (10)	Percent Change*: -30	*.01*	Percent Change*: -24	*NS*	
		Erythema Count location: Face.	Mid (10)	Measure: 2	*NS*	Measure: 3	*NS*	**NS**
		Papules (count) Count location: Face. Baseline counts: 29 (Target) / 41 (Comparator)	Mid (10)	Percent Change*: 75	*.01*	Percent Change*: -44	*.01*	**0.05**
		Peeling Count location: Face.	Mid (10)	Measure: 1	*NS*	Measure: 1	*NS*	**NS**
		Pustules (count) Count location: Face. Baseline counts: 13 (Target) / 13 (Comparator)	Mid (10)	Percent Change*: -57	*.03*	Percent Change*: -40	*.03*	**NS**
	B.07.04			**Gluconolactone**		**Vehicle**		
176 ↓ N=150 Parallel Mod/sev		**Inflammatory change (%)** Count location: Face.	Short (4)	Percent change: -49		Percent change: -39		**NS**
		Non-inflammatory change (%)	Short (4)	Percent change: -8		Percent change: -4		**NS**
		Total lesions change (%)	Short (4)	Percent change: -15		Percent change: -7		
		Inflammatory change (%)	Mid (12)	Percent change: -59	*.001*	Percent change: -10	*NS*	**0.05**
		Non-inflammatory change (%)	Mid (12)	Percent change: -17	*NS*	Percent change: -4	*NS*	
		Total lesions change (%)	Mid (12)	Percent change: -22	*.05*	Percent change: -5	*NS*	**NS**
				Glycolic acid + soybean liposome				
↑ N=40 Parallel split face		**Closed comedones (count)**						
		Open comedones (count)						

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.

Trial # Method	Compa-rison	Continuous Outcome Name (Units) Definition/Comments	Follow-up (wks)	Target		Comparator		Between P-value
					Within P		*Within P*	
246 ↑ N=40 Parallel split face Mild/mod		**Papules (count)**	Short (4)	Raw count: 20	*.005*	Raw count: 29	*.005*	**0.01**
		Closed comedones change (%)	Mid (12)	Percent change: -53		Percent change: -39		**0.01**
		Open comedones change (%)	Mid (12)	Percent change: -65		Percent change: -50		**0.01**
		Papules change (%)	Mid (12)	Percent change: -67		Percent change: -51		
		Pustules change (%)	Mid (12)	Percent change: -86		Percent change: -57		**0.01**

TRIAL: ↑↓ - presence of positive or negative methodological features (see Summary Table). "mild/mod," etc., - our assessment of entry severity of study patients. "P"- parallel study, "S"- split face design. TARGET and COMPARATOR: "Percent change"- an outcome derived from individual final and baseline measures; "Percent change*"- we calculated a group-based percentage change; "Change" - raw difference from baseline; "Change*" - calculated change; "Measure" - an outcome measure with no baseline comparison. SD: standard deviation. WITHIN P: P-value with respect to baseline in one arm. BETWEEN P-VALUE: comparison between Target and Comparator arms.